Skip to main content
Top
Published in: Annals of Hematology 2/2019

01-02-2019 | Letter to the Editor

(1-3)-β-d-Glucan serum increase and small-airway-invasive radiological findings as early signs of pulmonary aspergillosis in high-risk hematologic patients in the posaconazole era: preliminary observations

Authors: M. Picardi, R. Della Pepa, C. Giordano, N. Pugliese, C. Mortaruolo, F. Trastulli, F. Grimaldi, I. Zacheo, M. Raimondo, C. Sirignano, P. Salvatore, F. Pane

Published in: Annals of Hematology | Issue 2/2019

Login to get access

Excerpt

Dear Editor, …
Literature
2.
go back to reference Cornely OA, Cuenca-Estrella M, Meis JF, Ullmann AJ (2014) European society of clinical microbiology and infectious diseases (ESCMID) fungal infection study group (EFISG) and European confederation of medical mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases. Clin Microbiol Infect 20:1–4CrossRefPubMed Cornely OA, Cuenca-Estrella M, Meis JF, Ullmann AJ (2014) European society of clinical microbiology and infectious diseases (ESCMID) fungal infection study group (EFISG) and European confederation of medical mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases. Clin Microbiol Infect 20:1–4CrossRefPubMed
3.
go back to reference De Pauw B, Walsha TJ, Donnellya JP et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813–1821. https://doi.org/10.1086/588660.Revised CrossRefPubMedPubMedCentral De Pauw B, Walsha TJ, Donnellya JP et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813–1821. https://​doi.​org/​10.​1086/​588660.​Revised CrossRefPubMedPubMedCentral
5.
go back to reference Herbrecht R, Patterson TF, Slavin MA et al (2015) Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group. Clin Infect Dis 60:713–720. https://doi.org/10.1093/cid/ciu911 CrossRefPubMed Herbrecht R, Patterson TF, Slavin MA et al (2015) Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group. Clin Infect Dis 60:713–720. https://​doi.​org/​10.​1093/​cid/​ciu911 CrossRefPubMed
6.
go back to reference Patterson TF, Thompson GR, Denning DW et al (2016) Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 63:433–442CrossRefPubMedPubMedCentral Patterson TF, Thompson GR, Denning DW et al (2016) Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 63:433–442CrossRefPubMedPubMedCentral
7.
8.
9.
go back to reference Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JH, Wingard JR (2011) Executive summary: clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious diseases Society of America. Clin Infect Dis 52(4):427–431 Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JH, Wingard JR (2011) Executive summary: clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious diseases Society of America. Clin Infect Dis 52(4):427–431
10.
go back to reference Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405 Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405
11.
go back to reference Wiernik PH, Banks PL, Case DC, Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB (1992) Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 15;79(2):313–319 Wiernik PH, Banks PL, Case DC, Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB (1992) Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 15;79(2):313–319
12.
go back to reference Gandhi V, Estey E, Keating MJ, Plunkett W (1993)Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11(1):116–124 Gandhi V, Estey E, Keating MJ, Plunkett W (1993)Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11(1):116–124
19.
go back to reference Sheppard DC, Campoli P, Duarte RF (2014) Understanding antifungal prophylaxis with posaconazole in hematology patients: an evolving bedside to bench story. Haematologica 99:603–604CrossRefPubMedPubMedCentral Sheppard DC, Campoli P, Duarte RF (2014) Understanding antifungal prophylaxis with posaconazole in hematology patients: an evolving bedside to bench story. Haematologica 99:603–604CrossRefPubMedPubMedCentral
20.
go back to reference Nucci M, Anaissie E (2014) How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach. Blood 124:3858–3869CrossRefPubMed Nucci M, Anaissie E (2014) How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach. Blood 124:3858–3869CrossRefPubMed
21.
go back to reference Nucci M, Nouér SA, Cappone D, Anaissie E (2013) Early diagnosis of invasive pulmonary aspergillosis in hematologic patients: an opportunity to improve the outcome. Haematologica 98:1657–1660CrossRefPubMedPubMedCentral Nucci M, Nouér SA, Cappone D, Anaissie E (2013) Early diagnosis of invasive pulmonary aspergillosis in hematologic patients: an opportunity to improve the outcome. Haematologica 98:1657–1660CrossRefPubMedPubMedCentral
Metadata
Title
(1-3)-β-d-Glucan serum increase and small-airway-invasive radiological findings as early signs of pulmonary aspergillosis in high-risk hematologic patients in the posaconazole era: preliminary observations
Authors
M. Picardi
R. Della Pepa
C. Giordano
N. Pugliese
C. Mortaruolo
F. Trastulli
F. Grimaldi
I. Zacheo
M. Raimondo
C. Sirignano
P. Salvatore
F. Pane
Publication date
01-02-2019
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 2/2019
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-018-3441-3

Other articles of this Issue 2/2019

Annals of Hematology 2/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.